Synovics Pharmaceuticals, Inc. (SYVC) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSynovics Pharmaceuticals, Inc. (SYVC) trades at $0.0001. Synovics Pharmaceuticals, Inc. develops, manufactures, and commercializes generic over-the-counter (OTC) and prescription drug products in the United States. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for SYVC: SYVC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Synovics Pharmaceuticals, Inc. (SYVC) Healthcare & Pipeline Overview
Synovics Pharmaceuticals, Inc., a subsidiary of Maneesh Pharmaceuticals, focuses on the U.S. market, developing, manufacturing, and commercializing generic OTC and prescription drugs. Their product range includes common medications like analgesics and cold remedies, distributed through major drug store chains and wholesalers, addressing a consistent demand for affordable healthcare solutions.
What Is the Investment Thesis for SYVC?
Synovics Pharmaceuticals operates in the stable generic drug market, driven by consistent demand for affordable medications. The company's focus on OTC products provides a degree of resilience against economic cycles. However, with a negative profit margin of -15.4%, the company needs to improve operational efficiency. Key growth catalysts include expanding its product portfolio and penetrating deeper into existing distribution channels. The high beta of 83.17 indicates significant volatility relative to the market, presenting both opportunities and risks for investors. Successful execution of its growth strategies and improved profitability are crucial for long-term value creation.
Based on FMP financials and quantitative analysis
SYVC Key Highlights
Synovics Pharmaceuticals operates as a subsidiary of Maneesh Pharmaceuticals Limited, providing access to resources and expertise.
- The company focuses on generic over-the-counter (OTC) and prescription drug products, addressing a consistent demand for affordable medications.
- Synovics distributes its products through established channels, including chain drug stores, wholesalers, and distributors in the United States.
- The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives, targeting common consumer needs.
- Synovics Pharmaceuticals has a negative profit margin of -15.4%, indicating a need for improved operational efficiency.
Who Are SYVC's Competitors?
SYVC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SYVC's Key Strengths?
Established distribution network in the United States
- Expertise in generic drug development and manufacturing
- Focus on affordable medications
- Subsidiary of Maneesh Pharmaceuticals Limited
What Are SYVC's Weaknesses?
Negative profit margin (-15.4%)
- High beta (83.17) indicating high volatility
- Limited brand recognition compared to larger competitors
- Dependence on parent company for resources
What Are the Key Risks for SYVC?
Financial-distress signal — its Altman Z-Score of -6.49 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger generic drug manufacturers.
- Pricing pressures in the generic drug market.
- Regulatory scrutiny and compliance requirements.
- Product recalls and liability claims.
- Negative profit margin and high volatility.
What Are SYVC's Competitive Advantages?
- Established distribution network in the United States.
- Expertise in developing and manufacturing generic drugs.
- Focus on affordable medications, catering to price-sensitive consumers.
- Subsidiary of Maneesh Pharmaceuticals Limited, providing access to resources.
What Does SYVC Do?
Founded in 1983 and based in Fort Lauderdale, Florida, Synovics Pharmaceuticals, Inc. has evolved from its original incarnation as Bionutrics Inc. to become a key player in the generic pharmaceutical market. The company rebranded in 2006 to reflect its strategic shift towards developing, manufacturing, and commercializing a diverse portfolio of generic over-the-counter (OTC) and prescription drug products. Synovics operates as a subsidiary of Maneesh Pharmaceuticals Limited, leveraging its parent company's resources and expertise. Synovics focuses on the U.S. market, offering a range of OTC products including analgesics, cough, cold, antihistamines, asthma relief, and laxatives. These products are packaged and distributed through established channels, including chain drug stores, wholesalers, and distributors across the United States. The company's business model centers on providing affordable generic alternatives to brand-name medications, catering to the demand for cost-effective healthcare solutions.
What Products and Services Does SYVC Offer?
- Develops generic over-the-counter (OTC) pharmaceutical products.
- Manufactures generic OTC pharmaceutical products.
- Commercializes generic OTC pharmaceutical products.
- Develops generic prescription drug products.
- Manufactures generic prescription drug products.
- Commercializes generic prescription drug products.
- Packages and distributes products to chain drug stores.
- Supplies products to wholesalers and distributors in the United States.
How Does SYVC Make Money?
- Develops and manufactures generic drugs that are off-patent.
- Sells these drugs through established distribution channels.
- Generates revenue from the sale of OTC and prescription drugs.
- Focuses on providing affordable alternatives to brand-name medications.
What Industry Does SYVC Operate In?
Synovics Pharmaceuticals operates within the competitive biotechnology industry, specifically focusing on generic pharmaceuticals. The market for generic drugs is driven by patent expirations of brand-name drugs and the increasing demand for affordable healthcare solutions. The industry is characterized by intense competition, regulatory scrutiny, and pricing pressures. Synovics competes with larger generic drug manufacturers and distributors, requiring a focus on operational efficiency and strategic partnerships to maintain market share. The overall pharmaceutical market is expected to continue growing, driven by an aging population and increasing healthcare spending.
Who Are SYVC's Key Customers?
- Chain drug stores
- Wholesalers
- Distributors in the United States
- Consumers seeking affordable medications
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Synovics Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.49 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Synovics Pharmaceuticals, Inc. stands at 258.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.9%, showing how much profit it generates from its asset base. A current ratio of 0.53 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Synovics Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Fort Lauderdale, US. SYVC has traded publicly since 2004.
SYVC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
SYVC Latest News
No recent news available for SYVC.
SYVC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SYVC.
Price Targets
Wall Street price target analysis for SYVC.
SYVC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SYVC; grades run from A+ (80-100) to F (below 30).
Leadership: John R. Palmer
CEO
John R. Palmer is the CEO of Synovics Pharmaceuticals, Inc. His leadership is critical in guiding the company's strategic direction and overseeing its operations. As CEO, he manages a team of 155 employees, focusing on the development, manufacture, and commercialization of generic pharmaceutical products. His background likely includes extensive experience in the pharmaceutical industry, with a focus on generic drug development and commercialization.
Track Record: Due to limited information, John R. Palmer's specific achievements and strategic decisions at Synovics Pharmaceuticals, Inc. cannot be detailed. However, as CEO, he is responsible for the company's overall performance and strategic direction. His leadership is crucial in navigating the competitive generic pharmaceutical market and driving growth. The company's focus on affordable medications and established distribution network are likely key elements of his strategy.
SYVC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Synovics Pharmaceuticals, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This lack of stringent requirements can lead to increased risks for investors due to limited transparency and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- OTC Other tier companies are subject to less regulatory oversight, increasing the risk of fraud or manipulation.
- The company's financial health and performance are difficult to assess due to limited information.
- Potential for delisting or suspension from the OTC market due to non-compliance with regulations.
- Verify the company's registration and compliance with regulatory requirements.
- Assess the company's financial health and performance based on available information.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the risks associated with investing in an OTC Other tier company.
- Consult with a financial advisor before making any investment decisions.
- Check for any history of regulatory violations or legal issues.
- Subsidiary of Maneesh Pharmaceuticals Limited, providing some level of oversight.
- Established business operations since 1983.
- Focus on developing and manufacturing generic pharmaceutical products.
- Distribution network in the United States.
Synovics Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What do analysts say about SYVC stock?
There is currently no available analyst coverage or consensus on Synovics Pharmaceuticals, Inc. (SYVC) stock. The company's financial metrics include a negative profit margin of -15.4% and a high beta of 83.17, indicating significant volatility. Investors should conduct their own thorough research and due diligence before considering an investment in SYVC.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on Synovics Pharmaceuticals, Inc.
- OTC status and lack of analyst coverage require careful due diligence.